Syneos Health (SYNH) Lowered to Hold at Zacks Investment Research
Zacks Investment Research downgraded shares of Syneos Health (NASDAQ:SYNH) from a buy rating to a hold rating in a research note issued to investors on Friday morning.
According to Zacks, “INC Research Holdings, Inc. is a global contract research organization. It provides the full range of Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. Its services include clinical trial management services comprising patient recruitment and retention, project management, clinical monitoring, drug safety/pharmacovigilance, medical affairs, quality assurance, regulatory and medical writing, and functional service; and data services consisting of clinical data management, electronic data capture, and biostatistics. INC Research Holdings, Inc. is headquartered in Raleigh, North Carolina. “
Several other equities analysts also recently issued reports on SYNH. ValuEngine upgraded shares of Syneos Health from a hold rating to a buy rating in a research note on Saturday, November 10th. William Blair upgraded shares of Syneos Health from a market perform rating to an outperform rating in a research note on Friday, October 19th. UBS Group began coverage on shares of Syneos Health in a research note on Tuesday, October 9th. They issued a buy rating and a $60.00 price objective for the company. KeyCorp upped their price objective on shares of Syneos Health from $54.00 to $59.00 and gave the company an overweight rating in a research note on Friday, August 10th. Finally, Evercore ISI began coverage on shares of Syneos Health in a research note on Thursday, October 4th. They issued an outperform rating and a $58.00 price objective for the company. Three equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The company currently has a consensus rating of Buy and an average target price of $54.90.
Syneos Health (NASDAQ:SYNH) last issued its earnings results on Tuesday, November 6th. The company reported $0.75 EPS for the quarter, topping analysts’ consensus estimates of $0.58 by $0.17. Syneos Health had a negative net margin of 0.84% and a positive return on equity of 8.67%. The firm had revenue of $1.11 billion during the quarter, compared to the consensus estimate of $1.12 billion. The company’s revenue was up 88.3% on a year-over-year basis. On average, equities analysts forecast that Syneos Health will post 2.47 EPS for the current year.
Several large investors have recently made changes to their positions in SYNH. JPMorgan Chase & Co. raised its holdings in shares of Syneos Health by 1,589.5% in the third quarter. JPMorgan Chase & Co. now owns 1,319,875 shares of the company’s stock valued at $68,040,000 after buying an additional 1,241,754 shares during the last quarter. BlackRock Inc. raised its holdings in shares of Syneos Health by 10.3% in the third quarter. BlackRock Inc. now owns 8,035,926 shares of the company’s stock valued at $414,252,000 after buying an additional 751,050 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Syneos Health by 9.9% in the third quarter. Vanguard Group Inc. now owns 6,914,223 shares of the company’s stock valued at $356,429,000 after buying an additional 624,991 shares during the last quarter. Thrivent Financial for Lutherans raised its holdings in shares of Syneos Health by 3,641.8% in the third quarter. Thrivent Financial for Lutherans now owns 473,191 shares of the company’s stock valued at $24,393,000 after buying an additional 460,545 shares during the last quarter. Finally, Clearbridge Investments LLC raised its holdings in shares of Syneos Health by 13.3% in the third quarter. Clearbridge Investments LLC now owns 3,230,298 shares of the company’s stock valued at $166,522,000 after buying an additional 379,235 shares during the last quarter.
Syneos Health Company Profile
Syneos Health, Inc operates as an integrated biopharmaceutical solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various clinical development services spanning Phase I to Phase IV, including full-service global studies, as well as unbundled service offerings, such as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with drug development process.
Featured Article: What is the Dow Jones Industrial Average (DJIA)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Syneos Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syneos Health and related companies with MarketBeat.com's FREE daily email newsletter.